日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / State Council News

Nation issues new anti-monopoly guidelines for pharma sector

By Li Jiaying | chinadaily.com.cn | Updated: 2025-01-24 21:04
Share
Share - WeChat
Pharmacists dispense drugs at a hospital in Huzhou, Zhejiang province, in August. YI FAN/FOR CHINA DAILY

In an effort to safeguard fair market competition and protect consumer interests, the State Council's anti-monopoly commission officially issued new anti-monopoly guidelines on Friday targeting the pharmaceutical sector. 

A key highlight of the guidelines lies in the involvement of online platforms' monopolistic regulations. Given the rapid growth of online medical consultations and pharmaceutical e-commerce, the guidelines, for the first time, incorporate measures to address monopolistic practices in online medicine businesses, prohibiting platforms from engaging in the misuse of data, algorithms or platform rules.

The broad scope of the new guidelines also merits attention, which encompasses the entire pharmaceutical product chain — including traditional Chinese medicine, chemical drugs and biological products — compared to the previous version, which was largely concentrated in the limited realm of chemical active pharmaceutical ingredients (APIs).

"The pharmaceutical industry is highly technology-driven. Besides APIs, it also includes innovative drugs, patented medicines and generics. Every stage — from procurement and R&D to production, distribution and generic development — involves significant technological advancements and related protective strategies," said Zhou Wei, deputy director of the health law research center at Wuhan University, in an earlier interview. 

To further combat "false innovation", the guidelines also address a new type of patent monopoly behavior known as "product hopping". 

Product hopping refers to a strategy employed by original drug manufacturers to avoid or reduce competition from generic drugs, which mostly occurs shortly before the expiration of a patented drug and the entry of its generic counterpart and if applied inappropriately, could constitute an abuse of market dominance.

Factors for evaluation include whether the new patented drug represents a non-substantial improvement and whether the transition hinders or delays the entry of generics into the market, according to the guidelines.

"This is not about restricting the development of patented drugs but about regulating false innovation that fails to significantly improve a drug's efficacy, safety or utility," Zhou said.

Comprising seven chapters and 55 articles, the guidelines aim to provide detailed interpretations of monopolistic practices, enforcement principles and criteria for determining violations, offering a comprehensive framework to tackle anti-competitive behaviors in the pharmaceutical industry.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 最新亚洲国产 | 久久精品视频99 | 色橹橹欧美在线观看视频高清免费 | 国产网站在线 | 无码乱人伦一区二区亚洲 | av网址在线播放 | 三级福利视频 | 2018天天操夜夜操 | 久久这里只有精品99 | www.久久99| 丝袜捆绑调教视频免费区 | 成年人在线观看 | 1级a的观看视频 | 五月天婷婷网亚洲综合在线 | 久久国产欧美日韩精品 | 国产激情一区二区三区四区 | 日韩a级片 | 久久精品视频大全 | 精品久久一区二区 | 精品福利视频在线观看视频 | 狠狠色狠狠色 | 高清久久 | 久久久久久福利 | 国产主播在线看 | 视频一区二区在线观看 | 亚洲第一国产 | 色噜噜狠狠狠狠色综合久不 | 天天摸天天做天天爽在线 | 久久精品2 | 一级黄色片a | 国产婷婷精品av在线 | 国产一区二区视频在线播放 | 久久久久久免费播放一级毛片 | 天天做天天爱天天爽天天综合 | 午夜寂寞在线观看 | 日韩午夜激情视频 | 国产原创91 | 人人爽久久涩噜噜噜蜜桃 | 激情视频网站 | 色婷五月综激情亚洲综合 | 在线色 |